<DOC>
	<DOCNO>NCT00006385</DOCNO>
	<brief_summary>RATIONALE : Vaccines may make body build immune response kill tumor cell . Biological therapy sargramostim interferon alfa use different way stimulate immune system stop cancer cell grow . It yet know vaccine therapy effective without biological therapy melanoma . PURPOSE : Randomized phase II trial compare effectiveness vaccine therapy without biological therapy treat patient metastatic melanoma .</brief_summary>
	<brief_title>Vaccine Therapy With Without Biological Therapy Treating Patients With Metastatic Melanoma</brief_title>
	<detailed_description>OBJECTIVES : - Determine immune response vaccination melanoma associate antigen ( MART-1:27-35 , gp100:209-217 ( 210M ) , tyrosinase:368-376 ( 370D ) ) number peptide specific CD8+ T-cell precursor HLA-A2 positive patient metastatic melanoma . - Determine influence sargramostim ( GM-CSF ) and/or interferon alfa-2b ( IFN-A ) immune responses patient toxicity melanoma peptide vaccine . - Determine antitumor anti-pigmentary response may result immunization MART-1 , gp100 tyrosinase peptide , determine relationship clinical observation immune response lineage antigen without GM-CSF and/or IFN-A . - Compare relapse free survival overall survival patient treat melanoma peptide vaccine alone combination GM-CSF and/or IFN-A . OUTLINE : This randomize , multicenter study . Patients randomize 1 4 treatment arm . - Arm I : Patients receive multiepitope peptide ( MEP ) vaccine comprise MART-1:27-35 , gp100:209-217 ( 210M ) , tyrosinase:368-376 ( 370D ) peptide . Each peptide separately emulsify Montanide ISA-51 administer subcutaneously ( SC ) ( total 2 injection per peptide ) day 1 15 . - Arm II : Patients receive MEP vaccine arm I sargramostim ( GM-CSF ) subcutaneously ( SC ) daily day 1-14 . - Arm III : Patients receive MEP vaccine arm I interferon alfa-2b SC three time week . - Arm IV : Patients receive MEP vaccine arm I , GM-CSF arm II , interferon alfa-2b arm III . Treatment continue every 4 week maximum 13 course absence disease progression unacceptable toxicity . Patients follow every 3 month 2 year , every 6 month 3 year , annually thereafter . PROJECTED ACCRUAL : A total 92 patient ( 23 per arm ) accrue study within 13-16 month .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Freund 's Adjuvant</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven stage IV melanoma Measurable disease At least 1 lesion must minimum 1.0 cm diameter Bone metastases consider measurable disease No prior radiotherapy area measurable disease unless clearly progressive disease site measurable disease exists outside area prior radiotherapy HLAA2 positive No brain disease MRI CT scan within 4 week prior randomization Prior brain disease allow evidence active disease 2 successive MRI evaluation complete least 3 month apart PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 01 Life expectancy : Not specify Hematopoietic : WBC least 4,000/mm^3 Platelet count least 100,000/mm^3 Lymphocyte count great 700/mm ^3 Hepatic : SGOT great 2 time upper limit normal ( ULN ) Bilirubin great 2 time ULN Alkaline phosphatase lactic dehydrogenase great 2 time ULN Renal : Creatinine great 1.8 mg/dL Other : No significant detectable infection HIV negative No malignancy within past 5 year except : Any carcinoma situ Lobular carcinoma situ breast Carcinoma situ cervix Atypical melanocytic hyperplasia Melanoma situ Basal cell squamous cell skin cancer No autoimmune disorder condition immunosuppression Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : No prior MART1:2735 , gp100:209217 ( 210M ) , tyrosinase:368376 ( 370D ) peptide Greater 4 week since prior adjuvant immunotherapy , include sargramostim ( GMCSF ) interferon alfa2b Chemotherapy : At least 4 week since prior chemotherapy ( 6 week nitrosoureas mitomycin ) Endocrine therapy : At least 2 week since prior concurrent systemic corticosteroid , include oral steroid ( i.e. , prednisone , dexamethasone ) ; continuous use topical steroid cream ointment ; inhaler contain steroid Radiotherapy : See Disease Characteristics At least 4 week since prior radiotherapy local control palliation recover Surgery : Recovered prior major surgery</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2002</verification_date>
	<keyword>stage IV melanoma</keyword>
	<keyword>recurrent melanoma</keyword>
</DOC>